Background-There is a paucity of data in the literature on the risks associ
ated with, and optimal management of, pregnancy in patients with autoimmune
hepatitis (AIH).
Aims-To assess maternal and fetal outcomes in relation to clinical manageme
nt of pregnancy in a large cohort of patients with well defined AIH.
Methods-A review of all known pregnancies in 162 females with definite AIH
attending our clinics between 1983 and 1998, with respect to treatment, nat
ural history, and outcome.
Results-Thirty one live births (one twin) resulted from 35 pregnancies in 1
8 women (seven with cirrhosis). Median age at conception was 28 years (rang
e 18-36). Two patients presented with AIH de novo during pregnancy. At conc
eption, in 15 pregnancies patients had been receiving azathioprine alone or
(in nine) with prednisolone, in seven prednisolone alone, and in one cyclo
sporin. Fetal loss at greater than or equal to 20 weeks' gestation occurred
in two instances patients had been receiving azathioprine alone or (in nin
e) with prednisolone, in seven prednisolone alone, and within three months
or delivery in a further four. Among the 31 children born (median follow up
10 years) only two abnormalities have been identified: Perthes' disease in
one and severe mental and physical handicap in a second who was born prema
turely following decompensation of the mother's liver disease. Neither moth
er was receiving azathioprine.
Conclusions-Successful completion of pregnancy is a realistic expectation f
or patients with well controlled AIH. Treatment options vary, but azathiopr
ine appears to be generally safe and without adverse outcomes for mother or
baby. Vigilance is required, however, and patients need to be monitored ca
refully during pregnancy and for several months post partum.